Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 168

The DOI matches its Crossref record.

Evaluation of recombinant human bone morphogenetic protein‐2 as a bone‐graft substitute in a canine segmental defect model

Sciadini, Marcus F., Johnson, Kenneth D.·2000·Journal of Orthopaedic Research

Abstract

A study was performed in dogs to evaluate the dose‐response characteristics and effectiveness of recombinant human bone morphogenetic protein‐2 with a collagen sponge carrier in a segmental defect model. Twenty‐seven dogs underwent bilateral radial osteotomies with creation of a 2.5‐cm diaphyseal defect. All received autogenous cancellous bone graft in one defect and a collagen implant in the other. These implants contained recombinant human bone morphogenetic protein‐2 at the following doses: group 1 at 0 μg (three dogs, 0 μg/ml total implant volume), group 2 at 150 μg (three dogs, 50 μg/ml), group 3 at 600 μg (three dogs, 200 μg/ml), group 4 at 2,400 μg (three dogs, 800 μg/ml), group 5 at 0 μg (five dogs, 0 μg/ml), group 6 at 150 μg (five dogs, 200 μg/ml), and group 7 at 600 μg (five dogs, 50 μg/ml). The defects were stabilized with external fixators. The dogs in group 1–4 were killed at 12 weeks postoperatively, and those in groups 5–7 were killed at 24 weeks postoperatively except for one dog in group 7, which was killed at 48 weeks. Evaluation included monthly radiographs, biomechanical testing, and nondemineralized histology. All 27 radii with autogenous cancellous bone graft and all 19 implants treated with recombinant human bone morphogenetic protein‐2 achieved radiographic and histologic union and gross stability. The eight radii treated with collagen carrier alone went on to radiographic and histologic nonunion and were grossly unstable at death. A dose‐dependent occurrence of cyst‐like bone voids was noted radiographically and histologically. Biomechanical performance tended to be better at the lowest dose studied at 12 weeks, and all three doses performed better than the placebo (p < 0.05) at 12 and 24 weeks. By 24 weeks, radiolucent areas corresponding to histologic bone voids persisted radiographically, although there was evidence of early bone remodeling. This remodeling progressed to 48 weeks in the single animal followed to this time point, although bone voids remained. These radiologic findings were confirmed histologically. Recombinant human bone morphogenetic protein‐2 in a collagen sponge carrier has significant osteoinductive activity in this canine segmental defect model. A dose‐response relationship is evident, with heterotopic bone and cyst‐like void formation at higher doses and a minimum effective dose of 0‐150 μg. At 12 and 24 weeks postoperatively, biomechanical parameters achieved by defects treated with recombinant human bone morphogenetic protein‐2 were comparable with those of autograft controls and were significantly stronger than those of the placebo (p < 0.05).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/jor.1100180218

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 168

Metadata

Authors
Sciadini, M. F., & Johnson, K. D.
Venue
Journal of Orthopaedic Research
Publisher
Wiley
Published
2000-03
Volume
18
Issue
2
Pages
289-302
ISSN
  • 0736-0266 (ISSN-L)
  • 1554-527X
OpenAlex
W2003521990
Cited by
168
References
0
FWCI
7.75
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Evaluation of recombinant human bone morphogenetic protein‐2 as a bone‐graft substitute in a canine segmental defect model. https://app.cochat.ai/papers/10.1002/jor.1100180218
The paper
Sciadini, M. F., & Johnson, K. D. (2000). Evaluation of recombinant human bone morphogenetic protein‐2 as a bone‐graft substitute in a canine segmental defect model. Journal of Orthopaedic Research. https://doi.org/10.1002/jor.1100180218

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.